CCL2 and Miyoshi myopathy: Exosomes released from MM patients' BM-MSC modulate disease progression in vivo by increasing the exosome-based delivery of IL-6, CCL2 (C-C motif chemokine ligand 2), and fibronectin and decreasing expression of the tumor suppressor miR-15a.